CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE SIX MONTHS ENDED 30 JUNE 2026

CSPC Innovation Pharmaceutical Co., Ltd. ("**CSPC Innovation**"), a subsidiary of CSPC Pharmaceutical Group Limited (the "**Company**") listed on the ChiNext Market of Shenzhen Stock Exchange (Stock Code: 300765), published an announcement of its indicative results for the six months ended 30 June 2026 (the "**Indicative Announcement**") on 27 July 2026 on the information disclosure webpage of Shenzhen Stock Exchange's website at http://www.szse.cn/disclosure/listed/notice/index.html.

Set out in the appendix to this announcement (the "**Appendix**") is the Indicative Announcement prepared by CSPC Innovation in accordance with the China Accounting Standards for Business Enterprises in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

Shareholders and potential investors of the Company are reminded that the financial information of CSPC Innovation in the Appendix are the indicative results of CSPC Innovation for the six months ended 30 June 2026, rather than that of the Company. They should exercise caution when dealing in the securities of the Company.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 27 July 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.

APPENDIX

CSPC INNOVATION PHARMACEUTICAL CO., LTD.
2026 HALF YEAR INDICATIVE RESULTS

The company and all members of its board of directors warrant that the information disclosed is true, accurate and complete, and does not contain any false statements, misleading representations or material omissions.

I. INDICATIVE RESULTS FOR THE CURRENT PERIOD

(I) Period for the indicative results

1 January 2026 to 30 June 2026.

(II) Indicative results: Net profit is expected to be positive, representing a turnaround from loss to profit

Item	Current reporting period	Same period last year
Net profit attributable to shareholders of the listed company	Profit: 118,000 to 136,000 (in Ten Thousand Yuan)	Loss: 274.61 (in Ten Thousand Yuan)
Net profit after deducting non-recurring gains/ losses	Profit: 115,000 to 133,000 (in Ten Thousand Yuan)	Loss: 4,114.41 (in Ten Thousand Yuan)

II. COMMUNICATION WITH THE CPA FIRM

The financial data related to these indicative results have not been audited by the CPA firm. The company has conducted preliminary communications with the CPA firm on the financial information of the indicative results, and there is no disagreement between the company and the CPA firm regarding such financial information.

III. REASONS FOR THE CHANGES IN RESULTS

During the reporting period, the company continued to increase its investment in R&D and innovation, with a strategic focus on cutting-edge technology platforms such as antibody drugs, ADC and mRNA vaccines. The company steadily advanced the research and industrialisation progress of its biopharmaceutical business pipeline, with its product portfolio covering multiple core therapeutic areas, including oncology, metabolism and autoimmune diseases.

During the reporting period, the R&D achievements of the company's biopharmaceutical business continued to materialise. In January 2026, CSPC Megalith Biopharmaceutical Co., Ltd. ("Megalith Biopharmaceutical"), a controlled subsidiary of the company, entered into a strategic collaboration and license agreement with AstraZeneca to collaborate in the field of innovative peptide medicines development. Megalith Biopharmaceutical received the upfront payment of US$420 million in full from AstraZeneca on 29 May 2026. During the reporting period, in accordance with the performance obligations under the agreement and relevant accounting standards, Megalith Biopharmaceutical recognised a portion of the upfront payment as revenue. Meanwhile, in terms of product commercialisation, the company has obtained approval for the launch and sale of Enlonstobart Injection, Omalizumab for Injection and Ustekinumab Injection, with the commercialisation process continuing to advance steadily.

Taking into account the combined effects of the above factors, the company achieved a turnaround from loss into profit in the first half of 2026 compared with the same period last year and achieved a high level of profitability.

IV. OTHER RELEVANT EXPLANATIONS

The indicative results are based on preliminary estimates by the finance department of the company, and have not been audited by the audit firm. Detailed actual results should be referred to those to be disclosed in the 2026 interim report of the company. Investors are advised to make cautious decisions and pay attention to the investment risks.

Announcement is hereby made.

Board of Directors
CSPC Innovation Pharmaceutical Co., Ltd.
27 July 2026